Christian Kramer and Richard Lewis Pages 1896 - 1902 ( 7 )
The legacy of the advances made in high-throughput screening (HTS) in the 1990's is a large source of public data from which models can be derived using QSAR methods. This paper will examine the integrity of these public data sources and the implications for model building.
QSAR, high throughput screenings, drug discovery, error analysis, public databases
Novartis Institutes for Bio-Medical Research, Novartis Pharma AG, Forum 1, Novartis Campus, CH-4056 Basel, Switzerland.